Psychedelics After the Midterms: FDA Guidance, ICER’s Compass Psilocybin Review and Terran v. Compass Trial

This bulletin examines how recent US election results may affect psychedelic policy and drug development, including losses for figures associated with the Make America Healthy Again movement. It also reports that ICER will review Compass Pathways’ psilocybin treatment, a judge has sent Terran’s trade secrets case against Compass to trial, and DemeRx’s ibogaine lawsuit against atai was dismissed for now. Additional coverage includes FDA communication with the House Psychedelics Caucus about the limits of Special Protocol Assessments, patient treatment at registered Spravato sites, Jocasta’s options on Diamond’s non-hallucinogenic 5-HT2A agonists, Usona’s position in the psilocybin approval race, and proposed changes to drug scheduling. The bulletin presents these developments as signals for the commercial, regulatory, legal, and political direction of the psychedelic sector.